U.S. Capital Wealth Advisors’s ARK Genomic Revolution ETF ARKG Stock Holding History

U.S. Capital Wealth Advisors’s Portfolio ARKG Stock Details ARKG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-50	Closed	-$1.41K	–	688
2022 Q4	$1.41K	Buy	+50	New	+$1.59K	﹤0.01%	1513
2022 Q1	–	Sell	-3,325	Closed	-$204K	–	708
2021 Q4	$204K	Buy	3,325 +4	+0.1%	+$277	0.01%	681
2021 Q3	$248K	Buy	+3,321	New	+$279K	0.01%	647

Other funds holding ARKG

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

RJFSA

Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return

U.S. Capital Wealth Advisors's ARKG Position: Q1 2023 in Review

U.S. Capital Wealth Advisors sold out of ARK Genomic Revolution ETF (ARKG) in Q1 2023, closing a stake of 50 shares — an estimated $1.41K sold.

U.S. Capital Wealth Advisors first reported a position in ARKG in Q3 2021 and held it in 3 quarters. The position peaked at $248K in Q3 2021. 295 funds tracked by Wall St. Rank hold ARKG as of Q1 2023.

U.S. Capital Wealth Advisors reported no remaining ARK Genomic Revolution ETF position as of Q1 2023 after selling out during the quarter.
U.S. Capital Wealth Advisors sold 50 ARK Genomic Revolution ETF shares in Q1 2023, an estimated $1.41K.
U.S. Capital Wealth Advisors first reported a position in ARK Genomic Revolution ETF in Q3 2021 and held it in 3 quarters.
U.S. Capital Wealth Advisors's ARK Genomic Revolution ETF position peaked at $248K in Q3 2021.
295 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q1 2023.

Based on U.S. Capital Wealth Advisors's 13F filing for Q1 2023, filed 11 May 2023.